CLINICAL STUDIES AND CURQLIFE®

CurQlife® and Curcumin Absorption

CurQLife® is a patented turmeric formulation with extensive clinical trials, showing a 48-fold higher bioavailability than standard curcuminoids and 10x higher bioavailability than the market leading brand. * CurQLife® patent technology allows for 80% Curcuminoid release at 30 minutes and 95% dissolution within 1 hour. Most other turmeric brands have such a low percentage of absorption that the turmeric is disposed without use. CurQLife® has been proven to enter the bloodstream and remain for 24 hours at the recommended dosage level. Further, CurQLife® has the highest level of free curcumin entering the bloodstream than any other brand on the market. Why does this matter? If free Curcumin is not entering the bloodstream, the body will not utilize the positive benefits of turmeric.

*Industry Leaders represent the top 3 trademarked curcumin brands worldwide, including Meriva, Theracurcmin and BCN 95.

Osteoarthritis and Pain Relief

A 60 day clinical study was carried out with males and females from the age of 40-75 with Osteoarthritis symptoms in their knees. Subjects who met the inclusion and exclusion criteria were randomized into the study in a 1:1 ratio in CurQlife L (N=20) and Placebo group (N=20). The study consisted of six visits including screening visit, visit 1 (baseline), visit 2, visit 3, visit 4, and visit 5. Subjects were requested to take one capsule of CurQlife L or placebo twice daily after food.

The conclusion of this study was overwhelmingly supportive of the efficacy of CurQLife®. Patients experienced significant pain relief, a reduction in joint stiffness, and an increase in mobility, in comparison to the control placebo. Furthermore, zero patients had any adverse reactions. CurQLife® was shown to be effective against alleviating symptoms of knee osteoarthritis.

Additionally, at the end of the 2 month treatment period, the change in Total WOMAC score in CurQlife® was 94% over placebo. Knee flexion results showed 17 fold improvement over placebo. The WOMAC pain score reduced by 94.8% over placebo on 60 days of CurQlife® administration. The result also showed an improvement in knee stiffness in subjects supplemented with CurQlife® with reduction of 110.5% over placebo. The change in physical functioning from baseline over placebo was found to be 85.42% in CurQlife®. CurQlife® showed an excellent 300% reduction in LFI score from baseline score over placebo. An average 90% reduction in VAS scores from baseline over placebo was observed.